Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 16/20 | 0.43 |
| ▸ | NSD2 | O96028 | 1/20 | 0.43 |
| ▸ | SETD2 | Q9BYW2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21739138 | 1.00 | SMYD3 (0.43) | SMYD3NSD2SETD2MAPTMTNR1A | |
| SCHEMBL21739140 | 0.96 | SMYD3 (0.46) | SMYD3NSD2SETD2MTNR1AMTNR1B | |
| SCHEMBL21740347 | 0.93 | SMYD3 (0.50) | SMYD3NSD2SETD2 | |
| SCHEMBL22053226 | 0.90 | SMYD3 (0.39) | SMYD3NSD2SETD2MTNR1AMTNR1B | |
| SCHEMBL22051516 | 0.86 | SMYD3 (0.42) | SMYD3NSD2SETD2MTNR1AMTNR1B | |
| SCHEMBL21739209 | 0.84 | PTGES (0.35) | SMYD3MAPTMTNR1AMTNR1B | |
| SCHEMBL22053224 | 0.83 | SMYD3 (0.40) | SMYD3NSD2SETD2 | |
| SCHEMBL21740159 | 0.83 | SMYD3 (0.40) | SMYD3NSD2SETD2 | |
| SCHEMBL21740190 | 0.80 | SMYD3 (0.49) | SMYD3NSD2SETD2 | |
| SCHEMBL21739921 | 0.79 | EPHX1 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020112872-A1 | METHODS OF TREATING WHSC1-OVEREXPRESSING CANCERS BY INHIBITING SETD2 | Epizyme, Inc. (US) | 2020-06-04 | — | — | WO | disclosed |
| WO-2020037079-A1 | SUBSTITUTED INDOLES AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2020-02-20 | — | — | WO | disclosed |